Rocket Pharmaceuticals
RCKT· Manufacturing· Fiscal year ends in December
Gaurav D. Shah, M.D. is the CEO of Rocket Pharmaceuticals and was paid $3.5M in FY2025 (Dec), down 49%.
Executives3
See all- 1Christopher StevensChief Operating OfficerFY2025
- 2Gaurav D. Shah, M.D.Chief Executive OfficerFY2025
- 3Martin WilsonGeneral Counsel and Chief Corporate Officer, Senior Vice President, Interim Principal Financial OfficerNot disclosed
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allRocket Pharmaceuticals paid its 2 named executives $7.1M in total in FY2025 (Dec). CEO Gaurav D. Shah, M.D. was paid $3.5M of that.
| Name | |||
|---|---|---|---|
| Christopher StevensChief Operating Officer | Not disclosed | Not disclosed | |
| Gaurav D. Shah, M.D.Chief Executive Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers16
See allThe FY2023 (Dec) proxy of Rocket Pharmaceuticals names 16 peer companies for pay. Among Rocket Pharmaceuticals and these peers, CEO pay was the highest of 4 and total shareholder return was 2nd highest of 4.
1st highest of 4in Rocket Pharmaceuticals and its pay peers, FY2023 (Dec) by CEO pay:
2nd highest of 4in Rocket Pharmaceuticals and its pay peers, FY2023 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board1
See all- Gotham Makker, M.D.Director · 6 yr on the boardIndependentCompensation, Research & Development—Paid as an executive
The board of the latest proxy (FY2024).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 6, 2026 | FY2025 |
| Annual report | 10-K | Feb 26, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 30, 2025 | FY2024 |
| Annual report | 10-K | Feb 27, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 29, 2024 | FY2023 |
| Annual report | 10-K | Feb 27, 2024 | FY2023 |